arrow_down arrow_left arrow_right ca compl cross fav like login meta_cat meta_coms meta_date meta_mail meta_pages meta_reply meta_user meta_views next prev search sort speedbar tags fb gp mail od tw vk ya

УДК 616.988:578.834-06-053.2

Мультисистемний запальний синдром, асоційований із COVID-19 у дітей, є актуальною проблемою сьогодення. Мета роботи – ознайомити з особливостями перебігу та тактикою ведення пацієнтів дитячого віку із мультисистемним запальним синдромом, асоційованим із COVID-19 (MIS-C), проілюструвати власними клінічними спостереженнями. Матеріали і методи. Конкретні клінічні випадки з оцінкою клінічних симптомів, лабораторних показників, результатів додаткових обстежень та їх динаміки. Результати. Проаналізовано клінічні випадки, визначено особливості перебігу, складності діагностики, результати лікування. Висновки. MIS-C є складною клінічною проблемою, вимагає мультидисциплінарного підходу в питаннях діагностики та лікування.

Hematohidrosis (bloody sweat) is a symptom of trophic damage to the vascular wall, in which sweat mixes with blood and seeps onto undamaged areas of the skin in the form of red or pink liquid (depending on the ratio of sweat to blood). In our study we have analyzed 25 case reports of hematohidrosis in children, reported throughout the world using PubMed, ResearchGate with detailed description and opened access. We took into consideration: 
age of the patient, sex, location of bloody excretion, cause or trigger, treatment and its effectiveness. Our clinical case present a 9-year-old girl complained of a periodic bleeding from the intact skin of the face, neck, thighs (without visible damage to the skin) manifested by red or pink liquid, nosebleeds, and  bloody discharge from the mucous membrane of the eyes. The secretions were of varying intensity and lasted up to several hours. Most of all episodes are associated with a strong emotional exertion. One of the theories of hematohidrosis pathogenesis is evident vasoconstriction of the blood vessels surrounding the sweat glands, provoked by hyperactivation of the sympathetic nervous system, which is followed by their excessive vasodilation up to rupture and blood entering the sweat gland ducts. Capillary endothelial cells are known to contain β2-adrenoceptors, which, through the modulation of nitric oxide release, cause endotheliumdependent vasodilation. Blocking β-adrenoceptors (for example, propranolol) prevents excessive vasodilation of blood vessels and, accordingly, their rupture and blood flow to the sweat gland. We managed to find out that the patient’s bloody sweat was a manifestation of a separate pathological phenomenon, and not one of the symptoms of another disease. A properly formed treatment complex and the great trust of the parents enabled to stabilize the child’s condition, and later to cure her. Currently, hematohidrosis is recognized as an independent disease that requires in-depth study of the triggering mechanisms of development, pathogenetic and clinical features.

Acute respiratory tract infections (ARTI) place an enormous impact on patients and primary healthcare system due to their extraordinary incidence. In 2019, the world prevalence of ARTI reached 17.2 billion and accounted for 43.8% of all causes of the global disease burden [1]. Respiratory infections are the most common reason for seeking medical attention, with personal recurrence rates ranging from 2 to 6 times per year [2]. Although usually mild and self-limiting, ARTIs significantly affect work productivity and quality of life [3].

Emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing corona virus disease 2019 (COVID-19) brought a new challenge, being both common and severe, affecting upper and lower airways with considerable constitutional symptoms. As with other respiratory infections, the management of outpatients with mild COVID-19 without risk of progressing to severe disease, remains supportive and include close observation for early recognition of the life-threatening symptoms, reduction the risk of further SARS-CoV-2 transmission, advising on when to seek an in-person evaluation [4]. Absence of the effective specific measures in most COVID-19 cases serves a rationale for exploration of a new complementary approaches, one of which may be the use of probiotics.

Indirect evidence shows that patients with COVID-19 and diarrhea have more severe disease, increased concentration of inflammatory cytokines, markers of tissue damage, suggesting the intestinal cells can serve an additional entry and reservoir for SARS-CoV-2 [5, 6]. As with type II alveolar cells, intestinal and colonic enterocytes express angiotensin I converting enzyme 2 (ACE2), a receptor though which SARS-CoV-2 inoculates the body [7]. Bifidobacteria and lactobacilli adhering to enterocytes can hypothetically interfere with infection process and disease manifestation [8,9,10]. Interestingly that bacteria may potentially downregulate amide and peptide metabolism in the gut including angiotensin-converting enzyme 2 (ACE2) [11, 12]. It may explain the reason that cell cultures exposed to probiotics yielded lesser amount of transmissible gastroenteritis coronaviruses [13]. Additionally, the beneficial effects of probiotics in respiratory infections can be realized via several non-specific mechanisms discussed within the gut-lung axis paradigm [14], including enhancement of innate antiviral immune defense [15]. A recent systematic review of 23 randomized clinical trials involving a total of 6950 participants with ARTI, demonstrated fewer cases, shorter case duration, and reduced antibiotic prescription rates in patients taking probiotics [16].

The objective of this study was to assess the role of short-term ingestion of probiotics in mild symptomatic COVID-19, post-disease symptoms, and humoral immune response to SARS-CoV-2 in outpatients.